Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Abbott India said that it has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, ...

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Abbott's inquest into radiopharmaceuticals In 1946, Abbott became the first pharmaceutical company to have a special laboratory for radiopharmaceuticals – a move that led to the creation of the ...

The Company Manufacture pharmaceutical products, bulk drugs and chemicals. It was promoted by Abbott Laboratories, Chicago, U.S.A. which held 100% of the beneficial interest in the subscribed and ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

AbbVie's longtime CEO, Richard Gonzalez, who held his position since the business spun off from Abbott Laboratories in 2013, ...